PEM INTERACTIVE WEBINAR: DELAYED PRESENTATIONS AND PIMS-TS, A NEW DISEASE ENTITY TO WORRY ABOUT?

MAY 11, 2020



Wednesday May 13, 14:00 CEST

Many of us are wondering why children with serious illness are not coming to EDs or presenting very late in their disease course. And is this really so or just anecdote? Can we expect a spike in late presentations with easing of lockdowns throughout Europe?

Many of us are wondering if the PIMS-TS syndrome should alter their practice, when to do tests / what tests to do, what the natural disease course is etc. Many haven't actually seen patients; or they might have seen cases where in retrospect they suspect the disease.

Our speakers Dr. Damian Roland and Dr. Marilyn McDougall will have valuable contributions to your questions. Both are excellent speakers and leaders in their fields.

Register now and don't miss this opportunity to share your cases and ask your questions in this interactive webinar









PAEDIATRIC WEBINAR COVID-19:

Delayed presentations and PIMS-TS, a new disease entity to worry about?

Name: Damian Roland

Position: PEM Consultant and Chair of PERUKI

Country: United Kingdom





Paediatric Multi-system Inflammatory Syndrome temporally associated with SARS-CoV-2: PIMS-TS Something to worry about ??

Name: Marilyn McDougall

Position: Paediatric Intensive Care Consultant


Country: United Kingdom




April 2020

Daily New Cases

Cases per Day Data as of 0:00 GMT+0









- Italy, China & USA
- Significantly milder
- Overrepresentation : comorbities

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study



Haiyan Qiu*, Junhua Wu*, Liang Hong, Yunling Luo, Qifa Song, Dong Chen


The NEW ENGLAND JOURNAL of MEDICINE

CORRESPONDENCE

Children with Covid-19 in Pediatric **Emergency Departments in Italy**



Unexpected events ...



Hyperinflammatory shock in children during COVID-19 pandemic

South Thames Retrieval Service in tory shock, showing features similar London, UK, provides paediatric to atypical Kawasaki disease, Kawasaki intensive care support and retrieval

to 2 million children in South East England. During a period of 10 days in mid-April, 2020, we noted an unprecedented cluster of eight children with hyperinflammadisease shock syndrome, 1 or toxic shock one were well above the 75th centile

syndrome (typical number is one or two children per week). This case cluster formed the basis of a national alert.

All children were previously fit and well. Six of the children were of Afro-Caribbean descent, and five of the children were boys. All children except

COVID-19



S0140-6736(20)31094-1

www.thelancet.com Published online May 6, 2020 https://doi.org/10.1016/S0140-6736(20)31094-1



Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19



Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19

Case definition:

- A child presenting with persistent fever, inflammation (neutrophilia, elevated CRP and lymphopaenia) and evidence of single or multi-organ dysfunction (shock, cardiac, respiratory, renal, gastrointestinal or neurological disorder) with additional features (see listed in <u>Appendix 1</u>). This may include children fulfilling full or partial criteria for Kawasaki disease.
- Exclusion of any other microbial cause, including bacterial sepsis, staphylococcal or streptococcal shock syndromes, infections associated with myocarditis such as enterovirus (waiting for results of these investigations should not delay seeking expert advice).
- 3. SARS-CoV-2 PCR testing may be positive or negative

All stable children should be discussed as soon as possible with specialist services to ensure prompt treatment (paediatric infectious disease / cardiology / rheumatology*). There should be a low threshold for referral to Paediatric Intensive Care using normal pathways.



Presentation

History

Clinical Signs

- Fever $> 39^{\circ}$ C
- Skin and mucosal signs
- Gastrointestinal
 - Abdominal Pain
 - Diarrhoea
- Vasodilatory Shock
- Alert / lethargic









Investigations

Blood Results

- Low Sodium
- Elevated white cell count
 - Lymphopaenia
- Inflammatory Markers
 - CRP >100
 - PCT
 - Ferritin >500
 - Fibrinogen
- Cardiac Enzymes
 - Troponin
 - Pro_BNP








Pancarditis


Pericardial




Coronary arteries












Immediate Management

- Fluid resuscitation
 - 5-10ml/kg aliquots
- Vasopressors (movement)
 - Central IV access
 - Noradrenaline or Vasopressin
- Respiratory support :
 - non-invasive ventilation
 - Invasive
- Echocardiogram guide inotrope therapy
 - Function & coronary changes



Admitted 14th April-5th May






Laboratory values

Laboratory Data Evelina- median [IQR] Presentation Peak White cell count 10.7 (9.6-14) 18.6 (14.2-22.4) Lymphocyte Count* 1 (0.5-1.3) 0.4 (0.3-0.7) 150 (96 – 172) 129 (82 – 165) Platelets* **CRP** 211 (162 – 306) 307 (187 - 340)**D-dimers** 6.44 (3.7-10.2) 11.2 (6.5 -13.3) 924 (460 – 1534) 1023 (642 – 1834) Ferritin (µg/L) (14 -101) 45 (25 – 120) 110 (45 -251) Troponin T (ng/L) (0-13) NT – pro BNP (ng/L) (< 400 normal) 4708 (1542 - 9376) 7377 (3280 – 15670)

^{*} Minimum value

Cytokine storm



Assessment criteria

- Unpredictable
 - Course
 - Response to Rx

Treatment

- Immunomodulation
 - IVIG
 - Steroid
 - Biologic:
 - Anakinra
 - Infliximab
 - Tocilizumab

Management of sequelae

PIMS-TS Novel condition

Ongoing Assessment & management

Proactive and reactive

Multidisciplinary team involvement

- Organ specific features
 - PICU
- Cardiac specific
 - Cardiology team
- Infectious manifestations
 - PID team
- Inflammatory parameters
 - Rheumatology
- Sequelae
 - haematology team / psychology

Research



